Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.3890
+0.0170 (4.57%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.

The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types.

The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University.

The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.

Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics logo
Country United States
Founded 2015
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 52
CEO William Quinn

Contact Details

Address:
900 Chesapeake Drive
Redwood City, California 94063
United States
Phone 650 665 9295
Website boltbio.com

Stock Details

Ticker Symbol BOLT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001641281
CUSIP Number 097702104
ISIN Number US0977021049
Employer ID 47-2804636
SIC Code 2834

Key Executives

Name Position
William P. Quinn Chief Executive Officer, Chief Financial Officer, President, Secretary and Director
Grant Yonehiro C.F.A., M.B.A. Chief Operating Officer and Chief Business Officer
Sarah Nemec Senior Vice President of Finance and Principal Accounting Officer
Wesley Burwell Vice President and Head of Human Resources
Dr. Nathan Ihle Ph.D. Senior Vice President of Pharmaceutical Operations
Dr. Michael N. Alonso Ph.D. Senior Vice President of Research

Latest SEC Filings

Date Type Title
Apr 16, 2025 8-K Current Report
Apr 16, 2025 PRE 14A Other preliminary proxy statements
Apr 15, 2025 DEF 14A Other definitive proxy statements
Mar 24, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 24, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Jan 3, 2025 8-K Current Report
Dec 23, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 10-Q Quarterly Report